Clinical Application of AMH Measurement in Assisted Reproduction

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2020 Dec 28

PMID 33362720

Citations 9

Authors

Hang Wun Raymond Li

Scott M Nelson

Affiliations

Soon will be listed here.

Abstract

Anti-Müllerian hormone reflects the continuum of the functional ovarian reserve, and as such can predict ovarian response to gonadotropin stimulation and be used to individualize treatment pathways to improve efficacy and safety. However, consistent with other biomarkers and age-based prediction models it has limited ability to predict live birth and should not be used to refuse treatment, but rather to inform counselling and shared decision making. The use of absolute clinical thresholds to stratify patient phenotypes, assess discordance and individualize treatment protocols in non-validated algorithms combined with the lack of standardization of assays may result in inappropriate classification and sub-optimal clinical decision making. We propose that holistic baseline phenotyping, incorporating antral follicle count and other patient characteristics is critical. Treatment decisions driven by validated algorithms that use ovarian reserve biomarkers as continuous measures, reducing the risk of misclassification, are likely to improve overall outcomes for our patients.

Citing Articles

Anti-Müllerian hormone: biology and role in endocrinology and cancers.

Gowkielewicz M, Lipka A, Zdanowski W, Wasniewski T, Majewska M, Carlberg C Front Endocrinol (Lausanne). 2024; 15:1468364.

PMID: 39351532 PMC: 11439669. DOI: 10.3389/fendo.2024.1468364.

Investigating the potential role of α-SNAP in preventing chemotherapy-induced ovarian dysfunction: Insights from cellular and animal models.

Qin Y, Wen C, Hu B, Wu H Heliyon. 2024; 10(12):e32802.

PMID: 38994045 PMC: 11237948. DOI: 10.1016/j.heliyon.2024.e32802.

Serum anti-mullerian hormone, sex hormone, and nutrient levels in reproductive age women with celiac disease.

Tuerxuntayi A, Shi T, Gao B, Feng Y, Li T, Hui W J Assist Reprod Genet. 2024; 41(8):2129-2136.

PMID: 38907805 PMC: 11339009. DOI: 10.1007/s10815-024-03161-2.

Comparison of the multiples of the median of serum anti-müllerian hormone and pregnancy outcomes in patients with gestational trophoblastic disease: A case-control study.

Lai T, Lau L, Ngu S, Chu M, Chan K, Ng E Cancer Med. 2024; 13(7):e7134.

PMID: 38545760 PMC: 10973878. DOI: 10.1002/cam4.7134.

Barbagallo F, van der Ham K, Willemsen S, Louwers Y, Laven J J Clin Endocrinol Metab. 2024; 109(10):2561-2570.

PMID: 38486510 PMC: 11403310. DOI: 10.1210/clinem/dgae153.

References

Neves A, Blockeel C, Griesinger G, Garcia-Velasco J, La Marca A, Rodriguez I . The performance of the Elecsys® anti-Müllerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa. Reprod Biomed Online. 2020; 41(1):29-36. DOI: 10.1016/j.rbmo.2020.03.023. View

Hu K, Liu F, Xu H, Li R, Qiao J . Association of serum anti-Müllerian hormone and other factors with cumulative live birth rate following IVF. Reprod Biomed Online. 2020; 40(5):675-683. DOI: 10.1016/j.rbmo.2020.01.024. View

Li H, Wong B, Ip W, Yeung W, Ho P, Ng E . Comparative evaluation of three new commercial immunoassays for anti-Müllerian hormone measurement. Hum Reprod. 2016; 31(12):2796-2802. DOI: 10.1093/humrep/dew248. View

OBrien Y, Wingfield M, OShea L . Anti-Müllerian hormone and progesterone levels in human follicular fluid are predictors of embryonic development. Reprod Biol Endocrinol. 2019; 17(1):47. PMC: 6585091. DOI: 10.1186/s12958-019-0492-9. View

Iliodromiti S, Anderson R, Nelson S . Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2014; 21(6):698-710. DOI: 10.1093/humupd/dmu062. View

Nelson S, Klein B, Arce J . Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. Fertil Steril. 2015; 103(4):923-930.e1. DOI: 10.1016/j.fertnstert.2014.12.114. View

Broer S, Dolleman M, van Disseldorp J, Broeze K, Opmeer B, Bossuyt P . Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril. 2013; 100(2):420-9.e7. DOI: 10.1016/j.fertnstert.2013.04.024. View

Nardo L, Christodoulou D, Gould D, Roberts S, Fitzgerald C, Laing I . Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol. 2007; 23(8):486-93. DOI: 10.1080/09513590701532815. View

Moro F, Tropea A, Scarinci E, Leoncini E, Boccia S, Federico A . Anti-Müllerian hormone concentrations and antral follicle counts for the prediction of pregnancy outcomes after intrauterine insemination. Int J Gynaecol Obstet. 2016; 133(1):64-8. DOI: 10.1016/j.ijgo.2015.08.021. View

10.

Nelson S, Yates R, Fleming R . Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. Hum Reprod. 2007; 22(9):2414-21. DOI: 10.1093/humrep/dem204. View

11.

Broer S, Dolleman M, Opmeer B, Fauser B, Mol B, Broekmans F . AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2010; 17(1):46-54. DOI: 10.1093/humupd/dmq034. View

12.

Broer S, van Disseldorp J, Broeze K, Dolleman M, Opmeer B, Bossuyt P . Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2012; 19(1):26-36. DOI: 10.1093/humupd/dms041. View

13.

La Marca A, Sunkara S . Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2013; 20(1):124-40. DOI: 10.1093/humupd/dmt037. View

14.

Borini A, Cattoli M, Bulletti C, Coticchio G . Clinical efficiency of oocyte and embryo cryopreservation. Ann N Y Acad Sci. 2008; 1127:49-58. DOI: 10.1196/annals.1434.012. View

15.

Altman D, Royston P . The cost of dichotomising continuous variables. BMJ. 2006; 332(7549):1080. PMC: 1458573. DOI: 10.1136/bmj.332.7549.1080. View

16.

Li H, Lee V, Lau E, Yeung W, Ho P, Ng E . Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. PLoS One. 2013; 8(4):e61095. PMC: 3634063. DOI: 10.1371/journal.pone.0061095. View

17.

Nelson S, Anderson R, Broekmans F, Raine-Fenning N, Fleming R, La Marca A . Anti-Müllerian hormone: clairvoyance or crystal clear?. Hum Reprod. 2012; 27(3):631-6. DOI: 10.1093/humrep/der446. View

18.

Nyboe Andersen A, Witjes H, Gordon K, Mannaerts B . Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod. 2011; 26(12):3413-23. DOI: 10.1093/humrep/der318. View

19.

Ferraretti A, La Marca A, Fauser B, Tarlatzis B, Nargund G, Gianaroli L . ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011; 26(7):1616-24. DOI: 10.1093/humrep/der092. View

20.

van Rumste M, Custers I, van der Veen F, van Wely M, Evers J, Mol B . The influence of the number of follicles on pregnancy rates in intrauterine insemination with ovarian stimulation: a meta-analysis. Hum Reprod Update. 2008; 14(6):563-70. DOI: 10.1093/humupd/dmn034. View